Skip to main content
Fig. 2 | Alzheimer's Research & Therapy

Fig. 2

From: Long-term effects of immunotherapy with a brain penetrating Aβ antibody in a mouse model of Alzheimer’s disease

Fig. 2

Effects of acute antibody treatment in AppNL−G−F mice. A Study design: 5-month-old AppNL−G−F mice were treated with a single injection of PBS, RmAb158, or RmAb158-scFv8D3 (32 nmol/kg body weight). Brains were isolated after 3 days to analyze brain levels of Aβ. Quantification of soluble Aβ aggregates in TBS 16 K brain extracts of cortex and hippocampus (B) and in cortical TBS 100 K extracts (C). D Study design: 3-month-old AppNL−G−F mice were treated with three single injections of PBS, RmAb158, or RmAb158-scFv8D3 (32 nmol/kg body weight) during one week. Brains of treated mice, and a baseline group of non-treated 3-month-old mice, were isolated ten weeks later to analyze brain levels of Aβ. Quantification of Aβ aggregates in TBS 16 K brain extracts (E) and of Aβ1–42 in FA soluble extracts of the cortex, hippocampus, and cerebellum (F). ELISA quantification of soluble TREM2 (sTREM2) in TBS 16 K extracts from the acute (G) and seeding-inhibition (H) studies. Values represent mean and SD. Note that the unit in B, C, and E (pg/mg brain) differs from that in F (ng/mg brain). A and D were created with BioRender

Back to article page